This record was last updated May 13, 2026 (before its estimated June 5, 2026 completion). Its status may not reflect the trial's current state.
Summary
The main goal of this trial is to learn whether eptinezumab improves migraine symptoms and quality of life of participants with migraine who did not perceive a sufficient improvement during previous treatment with therapies targeting calcitonin gene-related peptide (CGRP).
Protocol Amendment History
6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2024-11-20; most recent amendment 2026-05-11.
Status change: Recruiting → Active, Not Recruiting2026-03-06
Status change: Not Yet Recruiting → Recruiting2025-01-14